Member Info for pickedpeck

That's one of the things that makes this special. There is a defensive core of holders that means they will only sell when they want to. No hostile or low bid can possibly work without the backing of that core of holders.

I can't see Dr Leire selling until there is significantly more value on the table from human data.

Why sell for £100m now when in 12 months time you can add a zero?

Anyone noticed when the stock is moving the 0 trades often appear? They don't seem to come up at other times. Could be just coincidence.

After every RNS lately Eric Leire has done a Proactive Investor interview. Today's should be a belter :)

This release shows again why they haven't released the methylation clock data yet, they are using it as bait and the big fish are biting. With stock as tight as it is, and a succession of positive news stories lining up this is absolutely primed.

Basically says we had two interested, now there are more, and the extra ones are the top tier of animal health companies.

It can only be because the data is compelling and can't be left to competition without at least a very good look. Essentially sounds like the start of a potential bidding war for the animal health partnership.

FOMO like this can only imply the data reveals a blockbuster.

Try asking AI what the likely sp would be of a company listing on the NASDAQ who has the existing Genflow technology patents, data, and proof points, plus partnerships, with suggestions of what the 2026 catalysts may do to the share price if achieved as expected. Maybe get it to do a three point estimate of low, expected, and high blue sky potential and what would it take to reach the blue sky option

The really interesting thing about the results will be Gad Berdugo's first statement as Chairman. Should layout his rationale for joining and also the strategy for the year ahead, maybe even hinting at Nasdaq.

Well no RNS today, can't be far away!

Genflow's year of catalysts looks set to continue, if not tomorrow then very soon.

1. Methylation clock data and muscle biopsies due imminently, possibility of first ever clinical evidence of rejuvenation in a large mammal.

2. Initial patents granted and finalised for SIRT6 centenarian variant, increasing the NAV of the company.

3. Animal health partnership announcement, two companies (at least) under CDA with access to the key data from the SLAB trial.

4. Glaucoma presentation at AAO, title and summary released in August. Potential for protection of eye ganglions, a revolution in the treatment of glaucoma.

5. Opthalmology partner / license agreement , following on from AAO Dr Leire has indicated that the company will license SIRT6 for opthalmology allowing the company to concentrate on MASH and Sarcopenia.

6. INDs for human trials for both MASH and Sarcopenia in 2027.

7. Maturation of the Acuitas partnership, with LNPs confirmed for eye and liver treatments.

If they get that lot done by the end of 2026 the company, share price, chat board, prospects and way ahead will be almost unrecognisable compared to now.

I found this paper by LEK consulting :

https://www.lek.com/sites/default/files/insights/pdf-attachments/future-animal-health.pdf

It doesn't mention Genflow specifically, but does imply that the future M&A targets in this space align exactly with Genflow's strategy.

I actually know the author on this, I worked with them on a major M&A piece a couple of years ago. LEK have huge industry respect and their word carries some weight in pharma circles.

Momentum building, a period as n/t today, likely UCLA data imminent. I think it will take a while for the full market reaction to the news once released, but should be pretty transformative if the science is independently confirmed. Language will switch from "does it work?" to "who will buy them?"

Word will spread, and those in now will be the early arrivals before the stampede by the herd.

Interesting times.

No idea why I follow the price and trades as closely as I do! Makes zero sense as I'm intending to hold to acquisition!

Would be nice to bring an end to this ridiculous mispricing though.

Just tried a relatively moderate block buy and it was n/t, the market makers are out of stock just as we come to the potential for a massive company defining news release. They have to move up today to try and shake some shares loose or face a potential catastrophe on Monday.

If the results for the SLAB (Dog Longevity) trial are released this Monday, we are looking for more than just a "yes or no" outcome. Because this is a pilot study (n=24), the data will likely be presented as a "Composite Success Signal."

​To determine if Genflow has a "Merck-grade" blockbuster on their hands, here are the specific benchmarks you should look for in the data:

​1. The P-Value "Tier" System

​Since there are only 6 dogs per group, a p < 0.05 is a massive win, but don't count them out if it's slightly higher.

​p < 0.05: Exceptional. This suggests the SIRT6 effect is so strong it overcame the small sample size. This is a "Buy" signal for big pharma.

​p < 0.10: Very strong for a pilot. This is called "Trend toward Significance." In a small cohort, this is usually enough to greenlight a larger Phase 2 study.

​Consistent p across groups: If the "High Dose Naked DNA" group has a better p-value than the "Low Dose," it proves a dose-response, which is statistically more important than a single p-value.

​2. The Methylation Clock (GrimAge/Biological Age)

​This is the "Truth Serum" of the trial. Watch for these two specific metrics:

​Age Deceleration: You want to see the "Biological Age" of the treated beagles significantly lower than the "Chronological Age."

​The "Reversal" Claim: If Eric Leire claims a 2-year reversal in a 10-year-old dog, that is a staggering result. Even a 6-month reversal in a short trial would be considered a major success, as it proves the SIRT6 is actively repairing DNA at the epigenetic level. This is headline level news.

​3. Muscle Mitochondrial Function (The Energy Factory)

​Since SIRT6's primary role is metabolic health and DNA repair, the muscle biopsies are where the "how" is proven.

​Mitochondrial Density: Look for an increase in the number or health of mitochondria in the muscle fibers. SIRT6 is known to reduce "oxidative stress" (the trash that clogs up cells).

​SIRT6 Expression is the most basic "Pass/Fail." Did the Naked DNA actually get into the muscle? If the biopsy shows high levels of SIRT6 protein in the treated dogs but none in the control, the delivery technology is a success.

This RNS will be data deep and scientifically important, but could also be a company defining moment. Maybe Monday, but definitely soon.

Zoetis are the logical second candidate for a CDA I agree.

Eric Leire’s professional history is relevant and interesting. He spent a significant portion of his career at Schering-Plough and Pharmacia (which, through a complex web of mergers, became parts of Pfizer and Merck/MSD).

The connection between his past at Intervet/Schering-Plough and the current Merck Animal Health (MSD) strategy is the "missing link" that explains why a small biotech company is pursuing a dog trial with such confidence.

1. The "Insiders" Connection

Eric Leire’s tenure at Schering-Plough coincided with when it was a powerhouse in veterinary medicine (Intervet).

Eric has mentioned in several investor forums that the "beagle trial" wasn't just a random lab experiment. It was a strategic recommendation from industry veterans in the animal health space (likely his former colleagues at Merck/MSD) who pointed out that the Veterinary Regulatory Pathway is significantly faster and cheaper than the human one.

Unlike human drug trials that take 10+ years, a veterinary product can reach the market in 3–5 years. For a company like Genflow, this provides a path to revenue while the high-stakes human trials for MASH and Glaucoma are still in the early phases.

2. Why the "Merck" Standard Matters

Because Eric knows exactly what Merck's M&A (Mergers and Acquisitions) team looks for, he has designed the GF-1004 (Dog Longevity) trial to be due-diligence ready.

The Facility (Syngene) is a world-class CRO that Merck itself uses.

The science is driving the study, they aren't just looking for "happier dogs." They are using the GrimAge Methylation Clock and biological biopsies, data points that a big pharma company like Merck requires to justify a multi-million dollar buyout.

3. The Strategy: "Validated by Association"

By aligning with the standards of his former employer, Eric is essentially running a live audition.

If the study (finishing in July, but key results imminent) shows that SIRT6 actually reverses the biological age of these 10-year-old beagles, Merck Animal Health (or Zoetis/Boehringer Ingelheim) doesn't have to guess if the science is good.

They already know the CEO, they know the lab (Syngene), and they recognize the clinical trial design.

The dog study isn't just about helping pets; it’s a liquidity event. By using Naked DNA (which is dirt cheap to manufacture) and the faster veterinary pathway, Genflow is trying to create a rapid commercial success story for SIRT6 that they can sell to Merck to fund their much more expensive human trials.

So, I'm pretty sure Merck is one of the companies covered by CDA, I wonder who the other one is? If the results are as good as we all hope will there be a partner auction? I'd like to think so.

Porter, the Google results are modified Gemini results. Try using the Gemini app directly, it will sort the data more directly for you.

You could even try that prompt I made the other day , someone has to eventually!

I'm thinking we may get the methylation clock data and mitochondrial activity results on Monday. It would fit with the two month window previously indicated, keep up their rate of one major RNS a week, and also be a good follow up to Acuitas and Bloom Burton this week.

I think it's possible mainstream media may pick up the story if the methylation clock data indicates rejuvenation in years. It could get very busy around here in the next couple of weeks if they do.

UCB are a huge company, definitely have cash for acquisitions, are also based in Belgium and have strong links to the Wallonia government and grant systems.

UCB also have a large ocular health investment and business unit which also fits perfectly with the Glaucoma program.

It seems like Genflow may be auditioning to become UCB's gene therapy department!

I missed it previously but the partnership slide in the Oxford presentation from Feb shows UCB as a collaborator / partner with Genflow on human sarcopenia. They are experimenting with Revatis technology to do photoporation in the GF-1005 program.

Why "Photoporation" is the Big Tech Secret:

In the Oxford video, Eric explains that the traditional way to deliver genes (using viruses) can be "irritating" or cause immune responses. Photoporation is their high-tech workaround:

Extract: They take myoblast progenitors (muscle stem cells) from the patient.

Laser Load: They use transient laser pulses to create tiny, temporary holes in the cell membrane.

Insert: The SIRT6 centenarian variant is slipped into the cell.

Re-inject: The "super-charged" cells are put back into the muscle.

This is a high-tech barrier to entry that protects Genflow from competitors in sarcopenia.

UCB has a growing interest in "Bone and Muscle" health (exemplified by their success with drugs like Evenity). Sarcopenia—the age-related loss of muscle mass — is a perfect therapeutic fit for their long-term pipeline.

Having the UCB logo on a "Strategic Partners" slide for GF-1005 suggests that UCB is likely the "First Look" partner. They may be providing the technical feedback or "Commercial Target" requirements that Genflow must hit to trigger a full licensing deal.

I got this wrong. They were able to successfully dose the dogs with naked DNA. That's super cheap and doesn't need the cold chain. It can't really be used for humans, but makes treatment a commodity for dogs.

I remember seeing Eric Leire say that Merck Animal Health were the original source of the idea to run the trial on dogs, makes me think they must be one of the prime candidates for partnership.